HOME > BUSINESS > Glenmark Pharma discovers potential new anti-cancer drug

Glenmark Pharma discovers potential new anti-cancer drug

glenmarkGlenmark Pharmaceuticals said its overseas subsidiary has discovered a molecule that can potentially be used in targeting even difficult-to-treat lung cancer and colorectal cancer.

The GBR 1372 molecule was discovered in the pharma company’s Swiss laboratory and that the company plans to file an application with the US Food and Drug Administration to approve the compound as a ‘investigational new drug’ or IND.

Unlike normal cancer drugs that try to control cancer by disabling epidermal growth factor receptor (EGFR), the new compound kills cancer cells through redirecting T cells to EGFR expressing cancer cells.

EGFR is a well-established target for lung cancer and colorectal cancer, Glenmark said.

Current drugs prevent signaling through EGFR by blocking ligand binding or inhibiting its protein kinase activity but they cause considerable side effects and are not active against cancers with Ras mutations.

Mutations in Ras genes continuously switch on intracellular signaling networks and make the tumors independent of stimulation by growth factor receptors such as EGFR and drugs that target EGFR are not currently indicated for patients with Ras mutations.

However, said the company, its new compound does not suffer from this limitation.

The company’s scientists were able to demonstrate preclinically that the new compound GBR 1372 is indeed equally active against EGFR expressing cancer cell lines – independent of their RAS mutation status.

Glenn Saldanha, Chairman & MD, Glenmark Pharmaceuticals said: “With the addition of GBR 1372, the quality of our biologics pipeline continues to improve. We continue to make strides as we transition to a global innovation led pharmaceutical organization.”

Dr. Fred Grossman, Chief Medical Officer, Glenmark Pharmaceuticals said he expected GBR 1372 to move into clinical development in the near future.

Follow ULTRA.news
Panacea Biotech, Serum Institute in polio vaccine tie-up Panacea Biotec said it signed two long-term agreements with the world's largest vaccine manufacturer, Serum Institute of India Pvt. Ltd, for manufacturing polio vaccines with a potential market size of $1.25 bln per year. The vaccine will also protect against six other diseas...
Ipca Laboratories acquires US pharma manufacturer for $9.65 mln Ipca Laboratories Ltd said it is has acquired US-based drug manufacturer Pisgah Labs Inc. for US$ 9.65 millions free of debt. The acquisition is aimed at establishing the company's foothold in the US market in the field of contract research and small-volume manufacturing of a...
Glenmark launches anti-inflammation drug based on Adalimumab Glenmark enters Adalimumab market Glenmark Pharmaceuticals said it has launched a biosimilar of Adalimumab, a drug for Plaque Psoriasis and Rheumatoid Arthritis from Cadila Healthcare Ltd.. "The launch of ADALY marks the launch of Glenmark’s first biosimilar in Dermatology...
OrbiMed Asia invests $7.5 mln more in Vivimed Labs unit Vivimed Labs said it will receive $7.5mn investment from OrbiMed Asia into its API business as a follow on to the $42.5 mn invested in September 2017. At the time, Vivimed has said that the proceeds will be utilised for debt reduction at the parent entity level as well as for...
Lupin gets USFDA nod for scalp solution Pharma Major Lupin announced that it has received final approval from the US Food & Drug Administration to market a generic version of Dovonex Scalp Solution from Leo Pharmaceutical Products Ltd. Calcipotriene Topical Solution is indicated for the topical treatment of chroni...
Sun Pharma’s eye drug application accepted by USFDA Sun Pharmaceutical Industries Ltd said the US FDA has accepted a New Drug Application (NDA) for its OTX-101 dry eye drug. The application will now be processed for approval. Dry eye is a condition in which the eye does not produce tears properly, or when the tears are not of t...
Suven gets neuro drug patents in India, Canada Suven Life Sciences Ltd said it has been granted one patent each in Canada and India for drugs for treating Neurodegenerative diseases. The Canadian patent 2932428 is valid through 2034 and the Indian patent 289123 is valid through 2028. The chemical entities are consider...
Lupin gets US approval for generic version of Bayer’s oral contraceptive Pharma Major Lupin said it got the approval of the US Food and Drug Administration to launch a generic version of Bayer's oral contraceptive Safyral. The branded version has annual sales of around $23 mln in the US. Lupin's product will be called Tydemy. The combination...
Glenmark reports successful trial for nasal spray, to file NDA soon Glenmark Pharmaceuticals, a global pharmaceutical company, today announced that its nasal spray Ryaltris met safety and efficacy goals in a Phase 3 clinical study in treating perennial allergic rhinitis. With the positive results, the company said it plans to submit an applica...
Neuland Laboratories acquires Hyderabad factory from Arch Pharma Pharma manufacturer Neuland Laboratories said it acquired a manufacturing plant located near Hyderabad from Arch Pharma Labs Limited. The facility is spread across 12 acres and has a capacity of about 197 KL, the company said. The plant was inspected by the USFDA in 2015, ...
Glenmark starts trials of blood cancer drug Glenmark Pharmaceuticals said it has started the clinical trial of its blood cancer drug GBR 1342 with the dosing of the first patient. “In just the last year, three of the Company’s biologics, two of which are immuno-oncology agents, have begun clinical trials, which is a te...
DENGUE DEATH: Haryana govt probe finds Fortis Hospital guilty An official inquiry by the Haryana government has found the Gurgaon Fortis hospital guilty of overcharging and several other violations of law, media outlets reported. Quoting the official copy of the report, Mirror Now said that the inquiry committee found the hospital guilty...
Eris Lifesciences completes acquisition of Strides Shasun India generics ops Pharma company Eris LifeSciences said it has completed its purchase of the India branded generics of Strides Shasun for Rs 500 cr in cash. "We now wish to confirm that the transaction ahs achieved closure," said Eris Lifesciences. Last month, Strides Shasun said it was sel...
Crucial win for Biocon as FDA approves cancer biosimilar trastuzumab Biocon and its partner Mylan scored a key victory on Friday as the US Food & Drug Administration approved its cancer-treating biosimilar trastuzumab. "Mylan anticipates potentially being the first company to offer a biosimilar to Herceptin, as a result of Mylan's ability to s...
Boosted by Jio’s success, Mukesh Ambani unveils his future plans Mukesh Ambani, India's richest man, said telecom was the first of his big bet, and he will now use his resources to solve problems in three other difficult areas -- agriculture, education and healthcare. Speaking at the HT Leadership Summit, Ambani said his primary motivation...
Glenmark registers first inhaler product in Europe Glenmark Pharmaceuticals said it has registered its Seretide Accuhaler product in the Nordic region of Europe, including Sweden, Denmark, Norway, Finland and Iceland. "The commercialization of the product would depend on national approval as well as substitution and pricing ...
EU accepts Biocon, Mylan’s application for cancer biosimilar pegfilgrastim Indian pharma company Biocon and its partner Mylan said EU authorities have accepted for review their applications for approving cancer treating biosimilars trastuzumab and pegfilgrastim submitted after completing corrective actions. The applications were resubmitted last mo...
Dr Reddy’s says EU approves production at Duvvada plant in Andhra Pharma major Dr Reddy's Laboratories said European Union authorities have again allowed it to produce drugs for sale in the EU region at its Duvvada factory in Andhra Pradesh. In its inspection conducted in September, the Regulatory Authority of Germany (Regierun von Oberbayer...
Panacea Biotec gets US nod for generic version of cancer drug Abraxane Panacea Biotec said it got the regulatory nod in the US for launching a generic version of big-selling cancer drug Abraxane. The drug will be sold with the help of Canadian pharmaceutical distributor Apotex. The annual sale of Abraxane worldwide is approximately US$973.4 m...
Dr Reddy’s gets served with class action lawsuit Pharma major Dr Reddy's Laboratories said it has been served with a class action lawsuit, originally announced in August, related to public disclosures made about regulatory action against the company. "Further to our intimation dated August 28, 2017 with regard to US Securit...